| Bid | 2.8 |
| Market Cap | 36.45M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.61 |
| PE Ratio (ttm) | -4.49 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3 |
| Volume | 740,997 |
| Avg. Volume (20D) | 1,817,800 |
| Open | 3.00 |
| Previous Close | 2.51 |
| Day's Range | 2.60 - 3.11 |
| 52-Week Range | 0.25 - 4.49 |
| Beta | undefined |
About NXL
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various m...
Analyst Forecast
According to 1 analyst ratings, the average rating for NXL stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 9.49% from the latest price.
Next Earnings Release
Analysts project revenue of $30.00K, reflecting a 46.08% YoY growth and earnings per share of -0.12, making a 20.00% increase YoY.
9 months ago · proactiveinvestors.com
Nexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veteransNexalin Technology has unveiled positive results from a clinical study evaluating its Gen-2 tACS 15 milliamp neurostimulation device to reduce pain in veteran patients with mild Traumatic Brain Injury...
